Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNBC-MERIT: RNA-Immunotherapy for Triple Negative Breast Cancer
NCT02316457Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- Oct 2016
- Primary completion
- May 2020
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of BNT114 and IVAC_M in triple-negative breast cancer (TNBC), sponsored by BioNTech SE. Primary endpoints: Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID at 120 days and Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID plus IVAC_M_uID at 246 days. Started Oct 2016; status: completed.
02
Drugs
BNT114IVAC_M
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02316457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316457.